A Phase I Dose Escalation Study of MK2206 in Combination With Standard Doses of Selected Chemotherapeutic or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2015
At a glance
- Drugs Carboplatin; Docetaxel; Erlotinib; MK 2206; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 29 May 2012 Actual end date changed from May 2011 to May 2012 as reported by ClinicalTrials.gov.
- 29 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2012 Actual patient number is 72 according to ClinicalTrials.gov.